MM Treatment: CAR T-Cell Therapy Selection and Insurance Considerations

Video content above is prompted by the following questions:

• How might you consider sequencing therapies for this patient? Please describe how you would approach treating this patient in your practice.
  • What factors impact your decision?
  • How do you incorporate patient preferences and quality of life considerations into the discussion when determining the sequencing of bispecifics and CAR T-cell therapy in R/R MM?
• Can BCMA-targeting bispecifics be used in patients who have received prior BCMA targeting CAR-T therapies?
  • Might you consider a different target?
• Might your strategy differ if the patient had received ide-cel instead of cilta-cel?